Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Immunoadsorption of LPS, IL-6 and C5a · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Immunoadsorption of LPS, IL-6 and C5a | PROCEDURE | - |
Inclusion Criteria: * Diagnosis of severe sepsis or septic shock (ACCP/SCCM) * Presence of 4 SIRS criteria/indicators * Suspected or proven infection (refer also to: 1.) * Age 18-80 * APACHE II score \> 18 * At least one acute organ dysfunction (renal/pulmonary/hemodynamics/cerebral) Exclusion Cri...
Immunoadsorption of LPS, IL-6 and C5a is an investigational therapy being studied for the treatment of septicemia, a serious bloodstream infection. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
Immunoadsorption of LPS, IL-6 and C5a is being developed by Pulmonx Corporation, a company traded on the stock exchange under the ticker symbol LUNG. The therapy is in Phase 2 clinical trials for septicemia.
Immunoadsorption of LPS, IL-6 and C5a is in Phase 2 clinical development. It is an investigational therapy for septicemia and has not been approved by the FDA or other regulatory agencies. One Phase 2 trial has been completed.
Immunoadsorption of LPS, IL-6 and C5a has been studied in one clinical trial, identified as NCT00146432, titled 'Immunoadsorption of LPS, C5a and IL-6 in Severe Sepsis and Septic Shock (ISASS-1)'. This Phase 2 trial was conducted in Germany and has been completed.
Immunoadsorption of LPS, IL-6 and C5a targets lipopolysaccharide (LPS), interleukin-6 (IL-6), and complement component C5a. These are molecules involved in the inflammatory response during sepsis, and the therapy aims to remove them from the blood.